Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Tolero Aims to File for AML Treatment Alvocidib in FY2018 in US: Sumitomo Dainippon
March 1, 2017
- Takeda to Transfer Part of CMC Functions to Bushu
March 1, 2017
- Kyowa Earns Rights for Astellas’ Extended-Release Quetiapine
February 28, 2017
- Shionogi to Comarket Methapain with Terumo
February 28, 2017
- Alecensa Gets Approval in Taiwan: Chugai
February 28, 2017
- Sanofi Files Atopic Dermatitis Treatment Dupilumab in Japan
February 28, 2017
- LEO Pharma Applies for Gel Formulation for Dovobet
February 28, 2017
- Daiichi Sankyo to Set Up Brand Strategy Unit to Spur Cancer Biz
February 27, 2017
- Eisai’s Yuji Matsue to Spearhead EA Pharma
February 27, 2017
- Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President
February 27, 2017
- Koichi Shimada to Lead Alfresa Pharma
February 24, 2017
- Takeda, Astellas to Build Joint Storage and Distribution System in Hokkaido
February 24, 2017
- JCR to Develop Pompe Disease Treatment Using Blood-Brain Barrier Technology
February 24, 2017
- Kyorin Holdings to Set Up Office in Indonesia
February 23, 2017
- Takeda Assigns High-Caliber Staffers for Govt’s Community-Based Care Initiative
February 22, 2017
- Generic Picks Will Depend on Regions as Joint Purchase Gets Underway, Iwasaki Says on Teva JV
February 22, 2017
- Debiopharm Takes Nippon Kayaku to Supreme Court over Elplat
February 22, 2017
- With Positive PIII Data, AZ Aims for Olaparib’s Japan Approval in 2018
February 22, 2017
- Chugai/Roche’s Alecensa Approved in Europe
February 22, 2017
- Takeda’s Consumer Healthcare Biz Split-Off Going as Scheduled
February 21, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…